Advisor Group Holdings, Inc. Genprex, Inc. Transaction History

Advisor Group Holdings, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.19 - $0.37 $1,767 - $3,441	9,300 Added 100.52%	18,552 $4,000
Q3 2023 Nov 13, 2023	SELL	$0.37 - $1.04 $3 - $10	-10 Reduced 0.11%	9,252 $3,000
Q4 2022 Feb 10, 2023	BUY	$1.0 - $58.8 $200 - $11,760	200 Added 2.21%	9,262 $13,000
Q2 2022 Aug 10, 2022	BUY	$1.28 - $2.31 $832 - $1,501	650 Added 7.73%	9,062 $13,000
Q3 2021 Nov 05, 2021	BUY	$2.59 - $3.36 $25 - $33	10 Added 0.12%	8,412 $22,000
Q2 2021 Aug 02, 2021	SELL	$3.11 - $4.87 $32,732 - $51,256	-10,525 Reduced 55.61%	8,402 $28,000
Q1 2021 May 13, 2021	SELL	$3.66 - $7.67 $232,593 - $487,428	-63,550 Reduced 77.05%	18,927 $82,000
Q4 2020 Feb 10, 2021	BUY	$3.03 - $5.51 $9,090 - $16,530	3,000 Added 3.77%	82,477 $342,000
Q3 2020 Nov 12, 2020	BUY	$2.9 - $4.29 $32,625 - $48,262	11,250 Added 16.49%	79,477 $267,000
Q2 2020 Aug 14, 2020	BUY	$1.99 - $3.64 $5,074 - $9,282	2,550 Added 3.88%	68,227 $214,000
Q1 2020 May 18, 2020	BUY	$0.28 - $6.23 $18,389 - $409,167	65,677 New	65,677 $159,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.